Biblio

Author Title [ Type

] Year

Filters: Author is Conticello, Concetta [Clear All Filters]

Journal Article

Leotta S, Pirosa MCristina, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MAnn, Martino EAntonia, Pelle ACurto, Leotta V, et al. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy. Chemotherapy. 2019:1-4.

Fazio M, Del Fabro V, Parrinello NLaura, Allegra A, Markovic U, Botta C, Accardi F, Vincelli IDonatella, Leotta S, Elia F, et al. Multiple Myeloma in 2023 Ways: From Trials to Real Life. Curr Oncol. 2023;30(11):9710-9733.

Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget. 2016.

Bringhen S, Petrucci MTeresa, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014.

Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.